α(v)β(3) integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo

Antibody-mertansine (DM1) conjugates (AMCs) are among the very few active targeting therapeutics that are approved or clinically investigated for treating various cancers including metastatic breast cancer. However, none of the AMCs are effective for the treatment of triple-negative breast cancers (...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Ping, Gu, Xiaolei, Cheng, Ru, Deng, Chao, Meng, Fenghua, Zhong, Zhiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667790/
https://www.ncbi.nlm.nih.gov/pubmed/29138558
http://dx.doi.org/10.2147/IJN.S146505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667790/
https://www.ncbi.nlm.nih.gov/pubmed/29138558
http://dx.doi.org/10.2147/IJN.S146505

Ejemplares similares